Meeting
2019 ASCO Annual Meeting
Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) versus GM-CSF adjuvant in patients with PSA-recurrent prostate cancer.
Authors
Glenn Liu
University of Wisconsin Carbone Cancer Center, Madison, WI
Glenn Liu , Lawrence Fong , Emmanuel S. Antonarakis , Jens C. Eickhoff , Ellen G. Wargowski , Laura E. Johnson , Robert Jeraj , Douglas G. McNeel
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary (Prostate) Cancer
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT01341652
Citation
J Clin Oncol 37, 2019 (suppl; abstr 5037)
DOI
10.1200/JCO.2019.37.15_suppl.5037
Abstract #
5037
Poster Bd #
149
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Phase II trial of a DNA vaccine encoding prostatic acid phosphatase (pTVG-HP) and nivolumab (Nivo) in patients (pts) with nonmetastatic, PSA-recurrent prostate cancer (PCa).
First Author: Hamid Emamekhoo
Poster
2016 ASCO Annual Meeting
Randomized phase II trial of a DNA vaccine encoding prostatic acid phosphatase (PAP) versus GM-CSF adjuvant in patients with biochemically recurrent prostate cancer.
First Author: Glenn Liu
Poster
2022 ASCO Genitourinary Cancers Symposium
A randomized phase 2 trial to evaluate the antitumor activity of enzalutamide (EZ) and talazoparib (TALA) for the treatment of metastatic hormone-naïve prostate cancer (mHNPC): ZZFIRST.
First Author: Joaquin Mateo
Poster
2017 ASCO Annual Meeting
Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Karim Boudadi